Food and Drug Administration Approves New Injection to Treat Double Chin

by Shirley Johanna on May 2, 2015 at 3:45 PM
Food and Drug Administration Approves New Injection to Treat Double Chin

The Food and Drug Administration (FDA) has approved the first drug to treat double chin that can eliminate neck fat in most people without surgery.

Kybella, commercial name of the drug is a deoxycholic acid made by Californa's Kythera Biopharmaceuticals based in Westlake Village, California.


Deoxycholic acid is a naturally occurring molecule in the body that helps to absorb fat. A licensed dermatologist can inject the drug under the jawline right into the fat tissue; the procedure takes only a few minutes. The drug destroys the cell membrane of submental fat, causing it to burst. It takes two to three days to heal.

According to a survey by the American Society for Dermatologic Surgery in 2014, about 68 percent of people were concerned about excess fat under the chin and neck. Kybella will be commercially available in June.

Kybella was approved after the manufacturer submitted 19 clinical studies involving nearly 2,600 patients. The clinical tests showed that kybella worked to eliminate moderate to severe chin fat.

Currently, surgery was the only other way to eliminate double chin with traditional liposuction.

According to the FDA, the most common side effects of Kybella are swelling, bruising, pain, numbness, redness and hardness in the treatment area.

"It is important to remember that Kybella is only approved for the treatment of fat occurring below the chin, and it is not known if Kybella is safe or effective for treatment outside of this area," said, Dr. Amy G. Egan, deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Drug News

Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Food and Drug Administration Approves New Injection to Treat Double Chin Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests